We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Knowledge about the novel clinical syndrome associated with SARS-CoV-2 pneumonia is rapidly and continuously evolving. The authors of this commentary previously evaluated the metabolomic profile of patients with severe COVID-19 pneumonia, and they propose that integration of these data with data from therapeutic drug trials may better predict clinical response.
Improved patient selection for therapeutic drug trials for COVID-19 is needed to identify those with the greatest potential for benefit. Metabolomic phenotyping is a novel personalized strategy with significant promise in the search for therapeutic options for patients with COVID-19.
– Kolene Bailey, MD
This abstract is available on the publisher's site.
Infection with the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) can lead to severe pneumonia, lung function impairment, and multiple organ failure that can be fatal (1). There are currently no FDA-approved therapies across the spectrum for patients affected with the coronavirus-induced disease of 2019 or COVID-19. However, several experimental approaches including repurposing of the RNA polymerase inhibiting antiviral agents have improved the health outcomes among COVID-19 patients (2).